The 9th Cardiovascular Outcome Trial (CVOT) Summit, held virtually on November 30-December 1, 2023, focused on recent outcomes trials and their implications for cardiovascular, kidney, and metabolic outcomes. Key trials discussed included DAPA-MI, SELECT, STEP-HFpEF, and CLEAR Outcomes, which evaluated the effects of dapagliflozin, semaglutide, bempedoic acid, and finerenone, respectively. These trials demonstrated significant benefits in reducing major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). The summit also addressed advances in managing type 1 diabetes (T1D), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Notable topics included the importance of diverse patient representation in clinical trials, the inclusion of patient-reported outcomes (PROs), and the development of innovative treatments for complications such as nonalcoholic steatohepatitis (NASH) and cancer. The summit emphasized the need for continuous evidence production and guideline updates to reflect the rapid advancements in diabetes and obesity management.The 9th Cardiovascular Outcome Trial (CVOT) Summit, held virtually on November 30-December 1, 2023, focused on recent outcomes trials and their implications for cardiovascular, kidney, and metabolic outcomes. Key trials discussed included DAPA-MI, SELECT, STEP-HFpEF, and CLEAR Outcomes, which evaluated the effects of dapagliflozin, semaglutide, bempedoic acid, and finerenone, respectively. These trials demonstrated significant benefits in reducing major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). The summit also addressed advances in managing type 1 diabetes (T1D), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Notable topics included the importance of diverse patient representation in clinical trials, the inclusion of patient-reported outcomes (PROs), and the development of innovative treatments for complications such as nonalcoholic steatohepatitis (NASH) and cancer. The summit emphasized the need for continuous evidence production and guideline updates to reflect the rapid advancements in diabetes and obesity management.